» Articles » PMID: 24909538

Determinants Associated with Bone Mineral Density Increase in Response to Daily Teriparatide Treatment in Patients with Osteoporosis

Overview
Journal Bone
Date 2014 Jun 10
PMID 24909538
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Several factors associated with bone mineral density (BMD) increase are reported with daily teriparatide treatment, but there has been no systematic analysis to summarize these associations. The purpose of this study was to investigate the clinical determinants associated with BMD increase to daily teriparatide treatment.

Methods: This was a retrospective study. We performed an analysis of 306 patients diagnosed with osteoporosis. Teriparatide was administered at 20μg/day for 12months. The primary efficacy measure was a change in lumbar spine (LS) BMD from baseline at 12months. To determine the response variables of BMD changes, we investigated the clinical determinants using univariate and multivariate analyses.

Results: There was a 9.8±8.2% increase in LS BMD after 12months. Prior bisphosphonate treatment and baseline procollagen type I N-terminal propeptide (PINP) concentration were significantly associated with LS BMD absolute response by univariate analyses. In the multiple regression model, patients with higher baseline PINP concentration had a significantly greater LS BMD absolute increase. Prior bisphosphonate use lost its correlation in the multiple regression models.

Conclusion: Our results showed that baseline PINP concentration was a useful predictor of LS BMD absolute increase regardless of prior treatment.

Citing Articles

Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.

Kong M, Gao C, Luan X, Fan C, Hao M, Jin C BMC Musculoskelet Disord. 2024; 25(1):109.

PMID: 38310278 PMC: 10837964. DOI: 10.1186/s12891-024-07227-1.


Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis.

Anna G, Anne-Lise F, Clemence D, Jean-Michel P, Florence T J Bone Miner Metab. 2023; 41(2):278-285.

PMID: 36894786 DOI: 10.1007/s00774-023-01412-3.


Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats.

Xi Y, Wang W, Ma L, Xu N, Shi C, Xu G Drug Deliv. 2022; 29(1):2386-2402.

PMID: 35869674 PMC: 9310824. DOI: 10.1080/10717544.2022.2086942.


Changes of lipid and bone metabolism in broilers with spontaneous femoral head necrosis.

Liu K, Wang K, Wang L, Zhou Z Poult Sci. 2021; 100(3):100808.

PMID: 33518301 PMC: 7936160. DOI: 10.1016/j.psj.2020.10.062.


Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial.

Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A JBMR Plus. 2018; 2(5):289-294.

PMID: 30283910 PMC: 6139701. DOI: 10.1002/jbm4.10054.